Abnova (Taiwan) Corporation (4133.TW)
TWD 28.0
(-2.95%)
TWD 28.0
(-2.95%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.35 Billion TWD | -1.39% |
| 2022 | 1.37 Billion TWD | 7.15% |
| 2021 | 1.28 Billion TWD | -0.89% |
| 2020 | 1.29 Billion TWD | 2.42% |
| 2019 | 1.26 Billion TWD | -2.39% |
| 2018 | 1.29 Billion TWD | -0.67% |
| 2017 | 1.3 Billion TWD | 4.45% |
| 2016 | 1.24 Billion TWD | -0.06% |
| 2015 | 1.24 Billion TWD | -4.5% |
| 2014 | 1.3 Billion TWD | 1.77% |
| 2013 | 1.28 Billion TWD | -0.53% |
| 2012 | 1.29 Billion TWD | -4.66% |
| 2011 | 1.35 Billion TWD | 1.58% |
| 2010 | 1.33 Billion TWD | 2.19% |
| 2009 | 1.3 Billion TWD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 1.38 Billion TWD | 1.92% |
| 2024 Q2 | 1.37 Billion TWD | -0.52% |
| 2023 Q3 | 1.36 Billion TWD | -3.17% |
| 2023 Q2 | 1.41 Billion TWD | 2.5% |
| 2023 Q4 | 1.35 Billion TWD | -0.79% |
| 2023 Q1 | 1.37 Billion TWD | 0.15% |
| 2023 FY | 1.35 Billion TWD | -1.39% |
| 2022 Q3 | 1.33 Billion TWD | 3.3% |
| 2022 FY | 1.37 Billion TWD | 7.15% |
| 2022 Q4 | 1.37 Billion TWD | 3.07% |
| 2022 Q2 | 1.29 Billion TWD | -0.55% |
| 2022 Q1 | 1.29 Billion TWD | 1.2% |
| 2021 Q2 | 1.3 Billion TWD | 1.51% |
| 2021 Q4 | 1.28 Billion TWD | 1.36% |
| 2021 Q1 | 1.28 Billion TWD | -0.44% |
| 2021 FY | 1.28 Billion TWD | -0.89% |
| 2021 Q3 | 1.26 Billion TWD | -3.25% |
| 2020 Q3 | 1.28 Billion TWD | 1.83% |
| 2020 FY | 1.29 Billion TWD | 2.42% |
| 2020 Q1 | 1.26 Billion TWD | 0.42% |
| 2020 Q2 | 1.26 Billion TWD | -0.32% |
| 2020 Q4 | 1.29 Billion TWD | 0.48% |
| 2019 FY | 1.26 Billion TWD | -2.39% |
| 2019 Q4 | 1.26 Billion TWD | -0.41% |
| 2019 Q3 | 1.26 Billion TWD | -2.68% |
| 2019 Q1 | 1.29 Billion TWD | 0.02% |
| 2019 Q2 | 1.3 Billion TWD | 0.69% |
| 2018 FY | 1.29 Billion TWD | -0.67% |
| 2018 Q2 | 1.29 Billion TWD | 0.17% |
| 2018 Q3 | 1.25 Billion TWD | -2.79% |
| 2018 Q1 | 1.29 Billion TWD | -0.95% |
| 2018 Q4 | 1.29 Billion TWD | 2.98% |
| 2017 Q4 | 1.3 Billion TWD | -1.43% |
| 2017 Q2 | 1.29 Billion TWD | 1.79% |
| 2017 FY | 1.3 Billion TWD | 4.45% |
| 2017 Q1 | 1.26 Billion TWD | 1.55% |
| 2017 Q3 | 1.32 Billion TWD | 2.51% |
| 2016 Q3 | 1.23 Billion TWD | -1.8% |
| 2016 FY | 1.24 Billion TWD | -0.06% |
| 2016 Q4 | 1.24 Billion TWD | 0.69% |
| 2016 Q2 | 1.26 Billion TWD | 0.61% |
| 2016 Q1 | 1.25 Billion TWD | 0.47% |
| 2015 FY | 1.24 Billion TWD | -4.5% |
| 2015 Q4 | 1.24 Billion TWD | 2.18% |
| 2015 Q3 | 1.22 Billion TWD | -4.58% |
| 2015 Q2 | 1.28 Billion TWD | -1.51% |
| 2015 Q1 | 1.3 Billion TWD | -0.56% |
| 2014 Q3 | 1.26 Billion TWD | -3.72% |
| 2014 FY | 1.3 Billion TWD | 1.77% |
| 2014 Q4 | 1.3 Billion TWD | 3.02% |
| 2014 Q2 | 1.31 Billion TWD | 1.53% |
| 2014 Q1 | 1.29 Billion TWD | 1.05% |
| 2013 Q3 | 1.26 Billion TWD | -4.92% |
| 2013 Q4 | 1.28 Billion TWD | 1.42% |
| 2013 FY | 1.28 Billion TWD | -0.53% |
| 2013 Q1 | 1.32 Billion TWD | 2.57% |
| 2013 Q2 | 1.33 Billion TWD | 0.55% |
| 2012 Q1 | 1.36 Billion TWD | 0.98% |
| 2012 Q4 | 1.29 Billion TWD | 0.89% |
| 2012 FY | 1.29 Billion TWD | -4.66% |
| 2012 Q2 | 1.38 Billion TWD | 0.94% |
| 2012 Q3 | 1.28 Billion TWD | -7.29% |
| 2011 Q4 | 1.35 Billion TWD | 4.03% |
| 2011 Q1 | 1.37 Billion TWD | 2.87% |
| 2011 Q2 | 1.39 Billion TWD | 1.52% |
| 2011 Q3 | 1.3 Billion TWD | -6.5% |
| 2011 FY | 1.35 Billion TWD | 1.58% |
| 2010 Q4 | 1.33 Billion TWD | 0.0% |
| 2010 FY | 1.33 Billion TWD | 2.19% |
| 2009 FY | 1.3 Billion TWD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Apex Biotechnology Corp. | 2.29 Billion TWD | 40.978% |
| Sinphar Pharmaceutical Co.,Ltd. | 6.25 Billion TWD | 78.312% |
| Panion & Bf Biotech Inc. | 3.23 Billion TWD | 58.094% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 5.17 Billion TWD | 73.785% |
| GenMont Biotech Incorporation | 1.65 Billion TWD | 17.992% |
| Adimmune Corporation | 9.48 Billion TWD | 85.706% |
| Tanvex BioPharma, Inc. | 2.76 Billion TWD | 50.939% |
| Polaris Group | 9.09 Billion TWD | 85.098% |
| Energenesis Biomedical CO.,LTD. | 828.57 Million TWD | -63.624% |
| UnicoCell Biomed Co., Ltd. | 685.92 Million TWD | -97.651% |
| PELL Bio-Med Technology Co. Ltd. | 1.41 Billion TWD | 4.401% |